About argenx SE - American Depositary Shares (ARGX)
Argenx is a biotechnology company focused on developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company utilizes its proprietary platform to discover and create monoclonal antibodies that target specific proteins in the immune system to modulate its response. By exploring a diverse pipeline of clinical-stage candidates, Argenx aims to address unmet medical needs and improve patient outcomes through its cutting-edge approaches in immunology and therapeutic development. Read More
Despite the Q1 miss, management reiterated confidence in its long-term “Vision 2030” strategy, highlighting strong Vyvgart uptake in gMG and CIDP and the recent U.S. approval of a self-injection option.
May 6, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT.
May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update.
